PE20120398A1 - Metodo mejorado para sintetizar pirfenidona - Google Patents

Metodo mejorado para sintetizar pirfenidona

Info

Publication number
PE20120398A1
PE20120398A1 PE2011002044A PE2011002044A PE20120398A1 PE 20120398 A1 PE20120398 A1 PE 20120398A1 PE 2011002044 A PE2011002044 A PE 2011002044A PE 2011002044 A PE2011002044 A PE 2011002044A PE 20120398 A1 PE20120398 A1 PE 20120398A1
Authority
PE
Peru
Prior art keywords
pyrphenidone
solvent
purified
toluene
extraction
Prior art date
Application number
PE2011002044A
Other languages
English (en)
Spanish (es)
Inventor
Ramachadran Radhakrishanan
Mike Cyr
Sabine Marie-Francoise Brigitte Boutet
Original Assignee
Intermune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43298478&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20120398(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intermune Inc filed Critical Intermune Inc
Publication of PE20120398A1 publication Critical patent/PE20120398A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/63One oxygen atom
    • C07D213/64One oxygen atom attached in position 2 or 6
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/63One oxygen atom
    • C07D213/64One oxygen atom attached in position 2 or 6
    • C07D213/6432-Phenoxypyridines; Derivatives thereof
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/34Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
    • A01N43/40Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
PE2011002044A 2009-06-03 2010-06-02 Metodo mejorado para sintetizar pirfenidona PE20120398A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18358809P 2009-06-03 2009-06-03

Publications (1)

Publication Number Publication Date
PE20120398A1 true PE20120398A1 (es) 2012-05-13

Family

ID=43298478

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011002044A PE20120398A1 (es) 2009-06-03 2010-06-02 Metodo mejorado para sintetizar pirfenidona

Country Status (35)

Country Link
US (6) US20110003863A1 (enExample)
EP (1) EP2440543B1 (enExample)
JP (2) JP5848244B2 (enExample)
KR (1) KR101734858B1 (enExample)
CN (1) CN102482255A (enExample)
AP (1) AP3630A (enExample)
AR (1) AR076974A1 (enExample)
AU (1) AU2010256693B2 (enExample)
BR (1) BRPI1011015B8 (enExample)
CA (1) CA2764043C (enExample)
CL (1) CL2011003069A1 (enExample)
DK (1) DK2440543T3 (enExample)
EA (1) EA021826B1 (enExample)
ES (1) ES2538103T3 (enExample)
GE (1) GEP20156223B (enExample)
HN (1) HN2011003187A (enExample)
HR (1) HRP20150696T1 (enExample)
HU (1) HUE026014T2 (enExample)
IL (1) IL216565A (enExample)
MA (1) MA33489B1 (enExample)
MX (1) MX2011012654A (enExample)
MY (1) MY162443A (enExample)
NI (1) NI201100211A (enExample)
NZ (1) NZ596872A (enExample)
PE (1) PE20120398A1 (enExample)
PL (1) PL2440543T3 (enExample)
PT (1) PT2440543E (enExample)
RS (1) RS54031B1 (enExample)
SG (1) SG176648A1 (enExample)
SI (1) SI2440543T1 (enExample)
TN (1) TN2011000615A1 (enExample)
TW (1) TWI434833B (enExample)
UA (1) UA106759C2 (enExample)
WO (1) WO2010141600A2 (enExample)
ZA (1) ZA201108794B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2296653B1 (en) 2008-06-03 2016-01-27 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
US10105356B2 (en) 2011-01-31 2018-10-23 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
EP4059499A1 (en) 2011-01-31 2022-09-21 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
MX2011007675A (es) 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
MX356551B (es) 2012-08-23 2018-06-04 Grupo Medifarma S A De C V Star Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné.
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
JP7066321B2 (ja) 2014-01-10 2022-05-13 アヴァリン ファーマ インク. エアロゾルのピルフェニドン及びピリドンのアナログの化合物、及び、その使用
JP6525437B2 (ja) 2014-04-02 2019-06-05 インターミューン, インコーポレイテッド 抗線維性ピリジノン
BR112017002980A2 (pt) * 2014-08-15 2017-12-12 Pixarbio Corp composição para inibir a inflamação em um indivíduo com um dano na coluna vertebral, método para tratar inflamação em um indivíduo tendo um dano na coluna vertebral e kit para produzir a composição
EP3307714A1 (en) * 2015-01-26 2018-04-18 Ulkar Kimya Sanayii Ve Ticaret A. S. An improved method for the synthesis and purification of pirfenidone
ITUB20154832A1 (it) 2015-10-29 2017-04-29 Procos Spa Processo per la sintesi di pirfenidone
CN105315198A (zh) * 2015-11-02 2016-02-10 重庆康乐制药有限公司 一种吡非尼酮的晶型及其制备方法
CN105330598B (zh) * 2015-12-02 2017-11-14 新发药业有限公司 一种吡非尼酮的制备方法
WO2017122139A1 (en) * 2016-01-14 2017-07-20 Laurus Labs Limited An improved process for the preparation of pirfenidone
US11066368B2 (en) 2016-01-14 2021-07-20 Laurus Labs Limited Process for the preparation and particle size reduction of pirfenidone
WO2017130166A1 (en) * 2016-01-31 2017-08-03 Granules India Limited An improved process for the preparation of highly pure anti-fibrotic drug
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
IT201600071672A1 (it) * 2016-07-08 2018-01-08 Dipharma Francis Srl Metodo per sintetizzare un farmaco immunosoppressore
IT201600108927A1 (it) * 2016-10-27 2018-04-27 Dipharma Francis Srl Metodo per sintetizzare un farmaco antifibrotico
US20180009753A1 (en) * 2016-07-08 2018-01-11 Dipharma Francis S.R.L. Method for preparing an antifibrotic agent
WO2018083709A1 (en) * 2016-11-07 2018-05-11 Msn Laboratories Private Limited, R&D Center Improved process for the preparation of pure 5-methyl-1-phenyl-2-1 (h)-pyridone
WO2018178996A1 (en) * 2017-03-28 2018-10-04 Natco Pharma Limited Improved process for the preparation of pirfenidone
WO2019028062A1 (en) 2017-07-31 2019-02-07 Washington University PIRFENIDONE DERIVATIVES FOR MODULATION OF B-LYMPHOCYTE ACTIVITY AND PROTECTION OF ORGANS
EP3494965B1 (en) 2017-12-11 2021-06-02 Laurus Labs Limited An improved process for the preparation of pirfenidone
CN112409246B (zh) * 2019-08-21 2023-04-07 北京凯因科技股份有限公司 一种吡非尼酮的晶型及其制备方法
CN115666533B (zh) * 2020-04-22 2024-08-09 永进药品工业株式会社 具有改善的安全性和稳定性的含吡非尼酮的肠溶包衣制剂及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3839346A (en) * 1972-12-18 1974-10-01 Affiliated Med Res N-substituted pyridone and general method for preparing pyridones
WO1992013844A1 (en) * 1991-01-31 1992-08-20 Warner-Lambert Company Substituted 4,6-di-tertiary-butyl-5-hydroxy-pyrimidines
JPWO2002085858A1 (ja) * 2001-04-20 2004-08-12 旭硝子株式会社 精製されたピペリジン誘導体の製造方法
WO2003014087A1 (fr) * 2001-08-06 2003-02-20 Asahi Glass Company, Limited Procede de preparation de 5-methyl-1-phenyl-2(1h)-pyridinone
CN1218942C (zh) 2002-06-11 2005-09-14 中南大学湘雅医学院 抗纤维化吡啶酮化合物及其生产工艺方法
CN100396669C (zh) * 2006-03-15 2008-06-25 浙江省医学科学院 一种抗纤维化药物吡非尼酮的制备方法
MX2007006349A (es) * 2007-05-29 2009-02-18 Cell Therapy And Technology S Nuevo proceso de sintesis para la obtencion de 5-metil-1-fenil-2-(ih)-piridona, composicion y uso de la misma.
CN101842355A (zh) * 2007-06-20 2010-09-22 奥斯拜客斯制药有限公司 作为纤维化抑制剂的取代的n-芳基吡啶酮
US20090131485A1 (en) * 2007-09-10 2009-05-21 Concert Pharmaceuticals, Inc. Deuterated pirfenidone

Also Published As

Publication number Publication date
PT2440543E (pt) 2015-07-03
MA33489B1 (fr) 2012-08-01
TWI434833B (zh) 2014-04-21
US20150065720A1 (en) 2015-03-05
AU2010256693A1 (en) 2012-01-12
BRPI1011015A2 (pt) 2018-02-14
EP2440543B1 (en) 2015-04-15
HN2011003187A (es) 2015-02-02
HRP20150696T1 (hr) 2015-08-28
BRPI1011015B8 (pt) 2021-05-25
TW201043602A (en) 2010-12-16
MY162443A (en) 2017-06-15
JP2016026196A (ja) 2016-02-12
ZA201108794B (en) 2013-03-27
JP5848244B2 (ja) 2016-01-27
PL2440543T3 (pl) 2015-09-30
EP2440543A2 (en) 2012-04-18
NZ596872A (en) 2013-12-20
BRPI1011015B1 (pt) 2020-11-10
IL216565A0 (en) 2012-03-01
US20110003863A1 (en) 2011-01-06
HUE026014T2 (en) 2016-05-30
JP2012528877A (ja) 2012-11-15
AU2010256693B2 (en) 2015-09-17
US20130345430A1 (en) 2013-12-26
CL2011003069A1 (es) 2012-05-25
AP2012006052A0 (en) 2012-02-29
NI201100211A (es) 2012-08-01
GEP20156223B (en) 2015-01-26
UA106759C2 (uk) 2014-10-10
CA2764043C (en) 2018-01-16
MX2011012654A (es) 2012-01-12
US20120016133A1 (en) 2012-01-19
US20150368200A1 (en) 2015-12-24
KR20120016277A (ko) 2012-02-23
TN2011000615A1 (en) 2013-05-24
SI2440543T1 (sl) 2015-06-30
EA201101695A1 (ru) 2012-05-30
KR101734858B1 (ko) 2017-05-12
EA021826B1 (ru) 2015-09-30
SG176648A1 (en) 2012-01-30
EP2440543A4 (en) 2012-11-21
WO2010141600A3 (en) 2011-04-21
WO2010141600A2 (en) 2010-12-09
AP3630A (en) 2016-03-08
RS54031B1 (sr) 2015-10-30
ES2538103T3 (es) 2015-06-17
US8519140B2 (en) 2013-08-27
IL216565A (en) 2015-06-30
DK2440543T3 (en) 2015-05-18
US20140221660A1 (en) 2014-08-07
CA2764043A1 (en) 2010-12-09
CN102482255A (zh) 2012-05-30
AR076974A1 (es) 2011-07-20

Similar Documents

Publication Publication Date Title
PE20120398A1 (es) Metodo mejorado para sintetizar pirfenidona
AR061924A1 (es) Proceso para elaborar 2- amino -5 - halobenzamidas 3- sustituidas
EA200702549A1 (ru) Способ производства органического соединения
BR112015018518A2 (pt) sistema e método para aplicar dióxido de carbono durante a produção de concreto
MX2014004943A (es) Composicion de grasa de sulfonato de calcio basada en carbonato de calcio y metodo de fabricacion.
AR067356A1 (es) Procesos para la preparacion de pirazoles
CL2013003127A1 (es) Metodo para recuperar un metal a partir de un mineral que contiene metales raros, preciosos o base que comprende poner en contacto el mineral con acido, sal de cloruro y un oxidante soluble bajo condicion seleccionada para formar un residuo de mineral y una solucion de lixiviacion oxidante soluble en acido que comprende el metal.
MX2015011435A (es) Amplificación de ácidos nucléicos.
CL2014001190A1 (es) Proceso para producir un reactivo nitrato ferrico para su uso en la etapa de lixiviacion en pilas de minerales de cobre que contienen fierro ii, que comprende concentrar fierro ii en una solucion de refino de cobre y mezclarlo con una solucion acuosa acida de nitrato de sodio; y proceso para la lixiviacion de cobre.
AR065775A1 (es) Procedimiento para preparar 2,6-dicloro-4-(trifluorometil)-fenilhidracina usando mezclas de dicloro-fluoro-trifluorometilbencenos
MX2019002816A (es) Proceso para la produccion de carbono puro, composiciones, y sus metodos.
MX390469B (es) Co-dispersiones de particulas de carbono grafeno y métodos para fabricar las mismas.
BR112013006210A2 (pt) dispositivo e método para dispensar duas soluções entre si numa etapa de extração por solventes
AR104790A1 (es) Método para la fabricación de agentes nucleantes para endurecimiento de hormigón
BR112015028740A2 (pt) processo para preparar dicarbamatos de 1,4:3,6-dianidroexitóis, composto químico precursor, composto químico derivado a partir de pelo menos um dos compostos químicos precursores, e, método de preparação de um composto químico derivado a partir de pelo menos um dos compostos químicos precursores
EA201300945A1 (ru) Улучшенные реагенты для экстракции металлов растворителем и их применение
MX386318B (es) Métodos y composiciones para caracterizar bacterias resistentes a fármacos a partir de muestras biológicas fijadas con formalina e incluidas en parafina.
CL2010001441A1 (es) Proceso para la preparacion de derivados de 2-amino tiazolonas sustituidas utilizando derivados de efedrina como base quiral.
DE112009001513A5 (de) Stabile Lysepuffermixtur zur Extraktion von Nukleinsäuren
ATE512931T1 (de) Verfahren zur herstellung von ammoniumheptamolybdat
WO2012038049A3 (en) Amplification of distant nucleic acid targets using engineered primers
AR089080A1 (es) Proceso de recuperacion de clorhidrato de nalmefeno
RU2014129826A (ru) Способы получения магнолола и его производных
CL2014002029A1 (es) Método para preparar un compuesto de formula 1 mediante la reacción de adición de michael , usando agua o acido o una mezcla de los mismos como aditivo, entre un compuesto de formula 2 y un compuesto de formula 3 en presencia de polvo de cobre.
AR104145A1 (es) Método de producción de epirrubicina, intermediario y sal farmacéutica

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed